Avecho Biotechnology Ltd has released a press release.
Avecho receives initial US$3M upfront payment from Sandoz
Filed with ASX ·
6ix hasn’t read this filing yet.
Avecho Biotechnology Limited on 6ix
Story so far
Earlier from Avecho Biotechnology
- Avecho and Sandoz enter exclusive license and development agreement to commercialise CBD for insomnia in Australia
- Avecho & Sandoz Sign Deal to Develop CBD for Insomnia in AUS
- Trading Halt
- Appendix 4E - Preliminary Final Report
- Response to ASX Price Query
Later from Avecho Biotechnology
- March 2025 Quarterly Activities Report & Appendix 4C
- Phase III Trial Update - New Sites Commence Recruitment
- Receipt of R&D Tax Incentive
- Phase III Insomnia Trial Recruitment Update
- June 2025 Quarterly Activities Report & Appendix 4C
Follow Avecho Biotechnology into a list and get an email when it puts out news.
Follow Avecho Biotechnology